<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03477266</url>
  </required_header>
  <id_info>
    <org_study_id>Ashrafnassif2002@yahoo.com</org_study_id>
    <nct_id>NCT03477266</nct_id>
  </id_info>
  <brief_title>Mouth Dissolving Mosapride Tables Enhance Post Cesarean Gut Recovery</brief_title>
  <official_title>Effectiveness of Mouth Dissolving Mosapride Tablets on Enhancing Gut Recovery After Cesarean Section: Randomized Double-blind, Placebo-controlled Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Benha University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Benha University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Giving women one day before and immediately after cesarean section a mouthly dissolving
      mosapride tablets 2every every 8 hours for maximum of 5 days ,or getting recovered
      gastrointestinal functions And assess preoperative gastrointestinal functions
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Uncomplicated post cesarean women one day before and immediately after elective cesarean
      receive 2 mouthly dissolving mosapride tablets every 8 hours maximum for 5 days and clinical
      care giver follow the woman's gastrointestinal functions, including intraoperative and
      postoperative nausea vomiting, passing flatus, hearing intestinal sounds, passing stools,
      occurring of paralytic ileus, length of the hospital stay
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">April 1, 2018</start_date>
  <completion_date type="Anticipated">August 1, 2018</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
    <masking_description>Color coded active tablets backed in red while identical dummy tablets coded in blue,both tablets are physically identical and usually no anticipated noticed side effects from mosapride</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Time of first flatus</measure>
    <time_frame>96 hours postoperative</time_frame>
    <description>Clinical</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Paralytic ileus incidence and its severity</measure>
    <time_frame>7days</time_frame>
    <description>Clinical</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toleration of fluids and solids intake</measure>
    <time_frame>2 weeks postoperative</time_frame>
    <description>Clinical</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of intraoperative and postoperative nausea and vomiting</measure>
    <time_frame>Intraoperative and 2 weeks postoperative</time_frame>
    <description>Clinical</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>First defecation</measure>
    <time_frame>2 weeks postoperative</time_frame>
    <description>Clinical</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Prevention of Postoperative Ileus</condition>
  <arm_group>
    <arm_group_label>Mouth dissolving mosapride</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fluxopride 5mg of Macryrl egypt 2 tablets one day before and immediately after elective cesarean section every 8hour for maximum of 5 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo mouth dissolving tablets</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Dummy identical tablets taken in the same way</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mosapride</intervention_name>
    <description>Intake mouthly dissolving mosapride tablets in immediate post cesarean section</description>
    <arm_group_label>Mouth dissolving mosapride</arm_group_label>
    <other_name>Fluxopride</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Oral Tablet</intervention_name>
    <description>Dummy identical tablets to mouthly dissolving mosapride tablets</description>
    <arm_group_label>Placebo mouth dissolving tablets</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  all women undergoing elective cesarean section

        Exclusion Criteria:

          -  prior abdominal surgery, abdominal adhesion, chronic constipation, allergy to
             mosapride
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>After cesarean section</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ashraf N Elmantwe, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Benha University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ashraf Nassif Elmantwe, MD</last_name>
    <phone>+201001801244</phone>
    <email>Ashrafnassif2002@yahoo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ashraf N Elmantwe, MD</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ashraf nassif Elmantwe</name>
      <address>
        <city>Banha</city>
        <state>Elqalopia</state>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ashraf Nassif Elmantwe, MD</last_name>
      <phone>+ 201001801244</phone>
      <email>Ashrafnassif2002@yahoo.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 21, 2018</study_first_submitted>
  <study_first_submitted_qc>March 23, 2018</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 26, 2018</study_first_posted>
  <last_update_submitted>March 27, 2018</last_update_submitted>
  <last_update_submitted_qc>March 27, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 29, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Benha University</investigator_affiliation>
    <investigator_full_name>ashraf nassif mahmoud elmantwe,MD</investigator_full_name>
    <investigator_title>Assistant professor</investigator_title>
  </responsible_party>
  <keyword>Postoperative ileus</keyword>
  <keyword>mosapride</keyword>
  <keyword>mouth dissolving tablets</keyword>
  <keyword>Intraoperative vomiting</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mosapride</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Once data collected and analyzed and published</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

